

Supplemental Amendment dated August 7, 2003
USSN: 09/349,915

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-49. (Cancelled)

1
Claim 50. (Currently Amended): A method for inducing *ex vivo* proliferation of a population of T cells, comprising contacting a population of T cells *ex vivo* with a solid phase surface having directly immobilized thereon:

(a) ~~a first agent~~ an anti-CD3 antibody or fragment thereof, which provides a primary activation signal to the T cells, thereby activating the T cells; and

(b) ~~a second agent~~ an anti-CD28 antibody or fragment thereof, which stimulates ~~an~~ a CD28 accessory molecule on the surface of the T cells, thereby stimulating the activated T cells, ~~the first agent the anti-CD3 antibody or fragment thereof~~ and ~~second agents the anti-CD28 antibody or fragment thereof~~ thereby inducing the T cells to proliferate.

Claims 51-52. (Cancelled)

Claim 53. (Currently Amended): The method of ~~claim 52~~ claim 50, wherein the anti-CD3 antibody is an anti-human CD3 monoclonal antibody.

Claims 54-56. (Cancelled)

Claim 57. (Currently Amended): The method of claim 50, further comprising:
monitoring proliferation of the T cells; and

Supplemental Amendment dated August 7, 2003
USSN: 09/349,915

reactivating and restimulating the T cells with the ~~first agent and second agents~~ the anti-CD3 antibody or fragment thereof and the anti-CD28 antibody or fragment thereof when the rate of T cell proliferation has decreased to induce further proliferation of the T cells.

Claim 58. (Previously Presented): The method of claim 57, wherein the step of monitoring proliferation of the T cells is by examining cell size or determining the level of expression of a cell surface molecule, and the step of reactivating and restimulating is initiated when T cell size has decreased or when the level of the cell surface molecule has decreased.

Claim 59. (Canceled)
